Skip to main content
Pay Bill Portals

MRD Testing vs. Traditional Cancer Monitoring: What’s the Difference?

Published Date

Traditional cancer monitoring relies on imaging and biomarkers like CA-125, but these methods often miss the earliest signs of recurrence. Enter MRD testing—a more sensitive, personalized approach.

  • Traditional Monitoring:
    Imaging detects tumors once they reach a certain size. CA-125 levels can fluctuate and aren’t always reliable.

  • MRD Testing with Signatera™:
    Tracks tumor-specific DNA in the blood, detecting recurrence months before scans and offers 100% sensitivity and specificity in ovarian cancer studies.

  • Tumor-Informed vs. Tumor-Naive:
    Signatera™ uses a tumor-informed approach, customizing the test to each patient’s unique cancer mutations for maximum accuracy.

MRD testing isn’t just a new tool—it’s a new standard. By catching recurrence earlier, it enables more timely treatment and greater peace of mind. For patients and providers alike, Signatera™ is a smarter way to monitor cancer.